Expert and Patient Perspectives on AE Management With FGFR Inhibitors in Cholangiocarcinoma


In Partnership With:

Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Taiho Pharmaceutical Co., Ltd., Lipika Goyal, MD, an associate professor of medicine (oncology) in the University Medical Line at Stanford Medicine in California, moderated an OncLive Insights webinar on best practices for using FGFR inhibitors in patients with cholangiocarcinoma and moderating adverse effects (AEs) in this patient population.

Goyal was joined by Katie Kelley, MD, a professor of clinical medicine in the Department of Medicine (Hematology/Oncology) and an affiliated faculty member in the Cancer Immunotherapy Program at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center; Caroline Kulhman, NP, a nurse practitioner at Massachusetts General Hospital in Boston; and Chaundra Bishop, a patient with cholangiocarcinoma.

In this exclusive conversation, Goyal, Bishop, Kelley, and Kuhlman discussed the current roles of the FGFR inhibitors pemigatinib (Pemazyre) and futibatinib (Lytgobi) in the cholangiocarcinoma treatment paradigm; common AEs associated with FGFR inhibitors; ways to counsel patients so they are prepared for the AEs they may experience while receiving FGFR inhibitors; and patient/provider communication barriers that still exist in this area.


That’s all we have for today! Thank you for listening to this episode of OncLive On Air, sponsored by Taiho Pharmaceutical Co., Ltd. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Hope Rugo, MD
Laura A. Huppert, MD
Michael D. Alvarado, MD, professor, surgery, Division of Surgical Oncology, Director, Breast Surgery Oncology Fellowship, Department of Surgery, University of California, San Francisco School of Medicine
A panel of 4 experts on gastrointestinal cancers
A panel of 4 experts on gastrointestinal cancers
A panel of 4 experts on gastrointestinal cancers
A panel of 4 experts on gastrointestinal cancers
A panel of 4 experts on gastrointestinal cancers
Chaundra Bishop
A panel of 4 experts on gastrointestinal cancers